Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration
Abstract Infantile hemangiomas (IHs) are the most common benign tumors in early childhood. They show a distinctive mechanism of tumor growth in which a rapid proliferative phase is followed by a regression phase (involution). Propranolol is an approved treatment for IHs, but its mechanism of action...
Main Authors: | Horacio Gomez-Acevedo, Yuemeng Dai, Graham Strub, Carrie Shawber, June K. Wu, Gresham T. Richter |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-60025-2 |
Similar Items
-
Propranolol for Treatment of Infantile Hemangioma: Efficacy and Effect on Pediatric Growth and Development
by: Rachel A. Giese, et al.
Published: (2021-01-01) -
Hemangioma infantil tratado com propranolol Propranolol treatment for hemangioma of infancy
by: Flavia Kakiuti Bonini, et al.
Published: (2011-08-01) -
Propranolol in the Treatment of Infantile Hemangiomas
by: Tan X, et al.
Published: (2021-09-01) -
Treatment of infantile hemangioma with propranolol
by: Gian Maria Pacifici -
Use of propranolol in infantile hemangioma
by: Manish K Shah, et al.
Published: (2017-01-01)